Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

Newton Golf Company Inc. (NASDAQ: NWTG) Surpasses 50 PGA TOUR Professionals Using Its Shafts, Cementing Status as TOUR-Trusted Innovator

  • Some 50 PGA TOUR professionals now play Newton shafts, validating the company’s rapid growth and elite performance standards.
  • Tour winners such as Miguel Ángel Jiménez, Doug Barron and Ken Duke credit Newton’s shafts for delivering superior control, distance and consistency.
  • The Fast Motion shaft, Newton’s latest innovation, continues to gain momentum with lightweight precision performance and increasing Tour adoption.

Newton Golf Company (NASDAQ: NWTG) has hit a major milestone in its mission to redefine golf shaft performance — more than 50 professionals across the PGA TOUR Champions and LPGA Tour have now used Newton shafts in competition (https://ibn.fm/5Mcdq). This marks a significant leap from earlier in the season, reflecting growing trust from elite players who value precision, consistency and innovation.

One of Newton’s most impactful endorsements came when Ken Duke became the first professional to officially sign with the brand, integrating the Newton Motion shaft into his bag for the 2024 season (https://ibn.fm/Q9jDe). His standout performance, ranking no. 1 in driving accuracy at the Constellation FURYK & FRIENDS (https://ibn.fm/V2aFq), highlighted the shaft’s consistency and power. “It’s unbelievable how I can shape it,” Duke said. “Not only that, but I’ve gained 6–15 yards with it.”

Duke introduced the shaft to fellow PGA TOUR Champions standout Doug Barron, who then made headlines by winning the 2024 Regions Tradition, his first major title, using Newton Motion (https://ibn.fm/TW96N). Barron saw “tighter dispersion and five more yards” after switching, which gave him “the confidence to win my first major championship.”

Back-to-Back Wins for Jiménez Using Newton Fast Motion

In a further show of validation, Miguel Ángel Jiménez, one of the most accomplished players on the PGA TOUR Champions, signed with Newton earlier this year (https://ibn.fm/dOlWg) — and has since won four PGA TOUR Champions victories (https://ibn.fm/7JVjG). Last month, he won the Kaulig Companies Championship, rallying to force a playoff and winning with a 20-foot birdie putt on the second extra hole. 

Prior to that, he had come out on top at the Principal Charity Classic at the Wakonda Club, the Trophy Hassan II in Morocco and the Hoag Classic in Newport Beach, California 

Jiménez currently leads the PGA TOUR Champions money list (https://ibn.fm/iPmsf), demonstrating the Newton shaft’s impact at the top tier. “Amazing that my game is still nice.” Jimenez said. “I still have a good distance from the tee, my irons are good, they’re sharp, and then [I] still enjoy what I’m doing. That to me is perfect. The only thing is keep counting. I hope it’s not the last one.”

A Lighter, Faster Shaft Built for Control

The Fast Motion shaft — Newton’s newest innovation — is a lighter Tour-proven option built from advanced high-modulus Toray carbon fibers (https://ibn.fm/UOc1o). The shaft reduces weight by ~10 grams vs. the Motion series while maintaining elite control and tight dispersion. Designed for faster swing speeds, the Fast Motion loads naturally for consistent timing and more powerful strikes.

Golf Magazine’s Kris McCormack said it best: “When you start seeing some of the best ball strikers of the last 30 years slotting Newton shafts into the bag, that’s not noise — that’s a signal.”

Innovation Driving Market Success

In fiscal year 2024, Newton Golf reported 887% YoY revenue growth, driven by the success of its proprietary shafts (https://ibn.fm/93tGl). The company’s strategy includes:

  • R&D focused on physics-first engineering
  • Shafts manufactured in the U.S. for quality control and logistics advantage
  • Direct-to-consumer and fitter-driven sales model
  • Strong presence across PGA TOUR Champions and growing LPGA adoption.

With more than 50 Tour players trusting Newton shafts and recent victories reinforcing the brand’s performance, Newton Golf is quickly establishing itself as a premier force in the golf-equipment industry.

For more information, visit the company’s website at www.NewtonGolfIR.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Newton Golf Comp. NWTG | Leave a comment

MissionIRNewsBreaks – BluSky AI Inc. (OTC: BSAI) to Acquire Land and 50MW Power Access for Delta Data Center Development

BluSky AI (OTC: BSAI), a modular AI infrastructure innovator, announced it has signed a non-binding letter of intent with Creekstone Energy LLC to acquire 25 acres within the Delta Data Center Development, including access to up to 50 megawatts of scalable power. The site, located within Creekstone’s Delta Gigasite in Utah, will serve as a foundation for BluSky’s next-generation SkyMod compute campuses designed to deliver secure, efficient, and sustainable AI infrastructure. CEO Trent D’Ambrosio said the project underscores BluSky’s commitment to building future-ready modular AI facilities, with groundbreaking anticipated in late 2026.

To view the full press release, visit https://ibn.fm/K3cVV

About BluSky AI Inc.

Headquartered in Salt Lake City, Utah, BluSky AI Inc. delivers modular, rapidly deployable data center infrastructure purpose-built for artificial intelligence. These next generation scalable AI Factories provide speed-to-market, and energy optimization for entities requiring high-performance infrastructure to support machine learning workloads. BluSky AI empowers small, mid-sized, enterprise, and academic partners from start-up to scale-up to drive innovation without compromise.

NOTE TO INVESTORS: The latest news and updates relating to BSAI are available in the company’s newsroom at http://ibn.fm/BSAI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in BlueSky AI Inc. BSAI | Leave a comment

MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. CLD-201, which received IND clearance in April, will enter a Phase 1 trial evaluating safety and efficacy in sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. Chief Medical Officer Guy Travis Clifton, M.D., said the milestone validates CLD-201’s potential to deliver durable, transformational treatment for patients with advanced tumors.

To view the full press release, visit: https://ibn.fm/HGzty

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.calidibio.com .

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Calidi Biotherapeutics Inc. CLDI | Leave a comment

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Highlights Rising Importance of Platinum in Electrical, Clean-Energy Applications

  • Platinum’s unique properties — exceptional conductivity, heat resistance and catalytic efficiency — make it indispensable across a range of electrical applications. 
  • Hydrogen fuel cells, particularly the proton exchange membrane variety, are one of the most promising sources of green energy production.
  • PLG is a player in this emerging landscape, with a focus on the development of large-scale platinum group metal resources in the Bushveld Complex.

As global industries search for scalable and sustainable energy solutions, platinum has emerged as a critical component in the future of electrical applications. Platinum Group Metals (NYSE American: PLG) (TSX: PTM), is well positioned to help meet this growing demand through its strategic operations in South Africa’s platinum-rich Bushveld Complex.

Platinum’s unique properties — exceptional conductivity, heat resistance and catalytic efficiency — make it indispensable across a range of industrial and electrical applications. From use in hard disk drives and thermocouples to spark plugs and oxygen sensors, platinum has long played a quiet but crucial role in technology and industry. However, the metal’s importance is rapidly evolving beyond conventional applications, thanks to the increasing demand for clean-energy solutions, particularly hydrogen fuel cells, which rely on platinum as a catalyst.

The growth of artificial intelligence has brought platinum into sharper focus as the world grapples with the energy demands of next-generation computing. A report by the Japan Exchange Group explains that training advanced AI models, such as ChatGPT, requires enormous power, with daily electricity consumption equivalent to that of 17,000 average U.S. households (https://ibn.fm/oY3Q1). This level of demand, especially when concentrated in large-scale data centers, presents serious environmental and sustainability challenges. As these AI models become more complex and integrated across industries, the pressure to reduce their carbon footprint is pushing the development of cleaner power alternatives.

One of the most promising of these alternatives is the hydrogen fuel cell, particularly the proton exchange membrane (“PEM”) variety that uses platinum to catalyze an electrochemical reaction between hydrogen and oxygen. Unlike traditional energy sources, hydrogen fuel cells do not rely on combustion and emit no carbon dioxide. Their only byproducts are water and heat (https://ibn.fm/V4Bvv). This makes them especially appealing as a stationary power source for energy-intensive data centers and AI operations. 

“Further, the hydrogen used by fuel cells can be produced through the electrolysis of water, powered by renewable energy sources such as wind and solar, making the energy provided completely fossil free,” reported the Japan Exchange Group. “The WPIC estimates that around a third of the global electrolyser market will rely upon platinum-containing PEM electrolysers.”

Platinum Group Metals is working to be a player in this emerging landscape. The company’s primary focus is the development of large-scale platinum group metal resources in the Bushveld Complex, a region responsible for producing roughly 75% of the world’s platinum supply (https://ibn.fm/VfthP). The company’s flagship project, the Waterberg Project, is one of the newest and largest undeveloped PGM resources in South Africa (https://ibn.fm/UCdzf). It is specifically designed to support low-cost, bulk mechanized mining, ideal for supplying high volumes of platinum to markets increasingly driven by technological and environmental innovation.

Waterberg is also notable for its high palladium content, another metal used in emissions control systems, as well as significant amounts of rhodium and gold. 

Platinum Group Metals continues to advance the Waterberg Project in partnership with leading industry players, including Impala Platinum Holdings Ltd., a major global PGM producer, Japan Organization for Metals and Energy Security and Hanwa Co., Ltd.  This joint venture provides PLG with technical and financial support as it moves toward development.  In addition, PLG and Valterra Platinum Limited are working together through joint venture corporation Lion Battery Technologies Inc. to develop next-generation lithium-sulphur battery technology that incorporates platinum and palladium into new cathode designs aimed at improving battery life, energy density and efficiency.

With rising global awareness around climate change, energy sustainability and the environmental cost of AI technologies, platinum’s relevance in clean, high-performance electrical systems is growing. Platinum Group Metals’ development activities place it at the heart of this transition, helping to supply a metal that is both critical to industry and environmentally beneficial.

For more information, visit www.PlatinumGroupMetals.net.  

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Platinum Group Metals Ltd. PLG | Leave a comment

MissionIRNewsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Completes Name and Ticker Change from Mullen Automotive

Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced that its previously disclosed name change from Mullen Automotive Inc. to Bollinger Innovations, Inc. is effective as of July 28, 2025, along with its new Nasdaq stock symbol “BINI.” The company stated the transition unifies its commercial Class 1, 3 and 4 vehicles under a single brand identity. CEO and Chairman David Michery said the move marks the completion of the company’s brand evolution while having no impact on its legal structure or operations. No shareholder action is required as a result of the changes.

To view the full press release, visit https://ibn.fm/RB9y6

About Bollinger Innovations, Inc.

Bollinger Innovations, Inc. (NASDAQ: BINI), effective July 28, 2025, and formerly, Mullen Automotive Inc. (Nasdaq: MULN), is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with U.S. based vehicle manufacturing located in Tunica, Mississippi. As of January 2024, both the ONE, a Class 1 EV cargo van, and THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of seven dealers, which includes Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Bollinger Innovations. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

To learn more about the Company, visit www.BollingerEV.com .

NOTE TO INVESTORS: The latest news and updates relating to BINI are available in the company’s newsroom at https://ibn.fm/BINI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Bollinger Innovations Inc. BINI | Leave a comment

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

  • Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need.
  • Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors.
  • Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025.
  • Clene is preparing to initiate a confirmatory Phase 3 ALS trial in the first half of 2026, with a separate MS (multiple sclerosis) program in late-stage development.

Investors looking for exposure to important biopharma innovation in underserved markets need to consider Clene (NASDAQ: CLNN). Clene and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for ALS, toward a potential FDA accelerated approval. 

Clene’s primary value proposition lies in its differentiated mechanism of action and its potential to secure a meaningful share of the large and growing ALS treatment market. CNM-Au8 is a suspension of gold nanocrystals designed to enhance mitochondrial function and protect neurons, an approach that targets the bioenergetic deficits believed to underlie ALS as well as other neurodegenerative diseases. This could be just the beginning. 

The company’s next inflection point is expected in Q4 2025, when it will report neurofilament light chain (“NfL”) biomarker results from over 150 ALS patients treated in the NIH-sponsored Expanded Access Program (“EAP”). Positive results would strengthen Clene’s case for a New Drug Application (“NDA”) under the FDA’s accelerated approval pathway. According to Clene, the FDA has responded constructively and accepted the basis for the company’s revised statistical analysis plan, which was recently resubmitted for final approval (https://ibn.fm/9EM0s).

Benjamin Greenberg, MD, Clene’s Head of Medical, said the FDA’s “constructive feedback” encourages the company to move forward. The company has also scheduled two additional FDA meetings in 3Q 2025: one to discuss long-term survival data from the HEALEY ALS Platform Trial and another to evaluate Phase 2 results from its multiple sclerosis program.

From an investor perspective, these regulatory discussions could unlock significant value for Clene by accelerating CNM-Au8’s path to market. Based on positive NfL results, Clene plans to launch a confirmatory Phase 3 trial, RESTORE-ALS, in the first half of 2026.

The broader market opportunity is also compelling. According to Research and Markets, the global ALS market was valued at $791.90 million in 2024 and is projected to grow at a CAGR of 5.40%, to reach $1.3 billion by 2034, driven by the rising incidence of ALS and aging populations (https://ibn.fm/qmuTf) CNM-Au8, if approved, would be an important addition to only a few commercially available treatments for ALS.

Clene is also advancing a parallel MS program with the same CNM-Au8 drug asset. Clene will meet with FDA in Q3 2025 for its End-of-Phase 2 meeting, planned to pave the way for a Phase 3 trial targeting cognitive improvement in people with MS. Cognitive dysfunction significantly impacts people living with MS, remaining a key unmet need in the treatment of Multiple Sclerosis.

For investors, Clene’s value lies in its multiple shots on goal: regulatory catalysts in both ALS and MS, ongoing data generation, and a novel therapeutic platform. While clinical-stage biotechs carry inherent risks, the company’s unique approach could significantly shorten its path to commercialization and generate early revenue from a patient population with limited options.

Clene’s differentiated technology and advancing clinical programs position it as a company to watch with important investment potential in the evolving neurodegenerative therapy space.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder and former CEO of Oncoceutics Inc., brings over 20 years of experience in biotechnology leadership and financial markets, with a track record in developing targeted therapies for solid tumors, including HK327M-mutant gliomas. Oncoceutics was acquired by Chimerix Inc. (NASDAQ: CMRX) for $450 million in 2021 and later by Jazz Pharmaceuticals for $935 million in April 2025. Lantern CEO Panna Sharma said Dr. Schalop’s expertise in neurooncology and strategic transactions aligns with Lantern’s AI-powered drug development platform and its CNS cancer pipeline at subsidiary Starlight Therapeutics. Dr. Schalop said he looks forward to helping accelerate the company’s precision oncology programs to deliver novel therapies for patients with limited treatment options.

To view the full press release, visit https://ibn.fm/b8EfM

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Lantern Pharma Inc. LTRN | Leave a comment

MissionIRNewsBreaks – Ucore Rare Metals Inc.’s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Core to Blueprint to Secure Rare Earth Independence

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioned as a key player in a strategy to build a secure, independent rare earth supply chain in North America. Triggered by China’s export restrictions on key elements, a potential blueprint includes diversifying rare earth sources, using modular refining with Ucore’s RapidSX(TM) technology, anchoring refining with magnet-making hubs, establishing stockpiles and off-take agreements, and proving the chain with traceability and ESG standards. Ucore’s RapidSX(TM) is central to reducing bottlenecks in chemical separation, helping to develop a resilient, transparent, and strategically independent supply chain. 

To view the full article, visit https://ibn.fm/JDlfa

About Ucore Rare Metals Inc.

Ucore is focused on rare- and critical-metal resources, extraction, beneficiation and separation technologies with the potential for production, growth and scalability. Ucore’s vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry. Through strategic partnerships, this plan includes disrupting the People’s Republic of China’s control of the North American REE supply chain through the near-term development of a heavy and light rare-earth processing facility in the U.S. state of Louisiana, subsequent strategic metals complexes (“SMCs”) in Canada and Alaska and the longer-term development of Ucore’s 100% controlled Bokan-Dotson Ridge Rare Heavy REE Project on Prince of Wales Island in Southeast Alaska, USA. For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Ucore Rare Metals Inc. UURAF | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB): Innovation Meets Science Through Scalable Platform  

Nutriband (NASDAQ: NTRB) is positioning at the forefront of abuse-deterrent drug delivery in advancing its flagship fentanyl patch and buprenorphine candidates. The company combines transdermal innovation with abuse-deterrent science to meet critical public health needs. According to Nurtiband, AVERSA Fentanyl, with the possibility to reach peak annual U.S. sales of $80 to $200 million, holds the potential to be the world’s first opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. In addition, Nutriband is advancing AVERSA Buprenorphine, which upon approval is projected to achieve peak U.S. sales between $70 and $130 million. Both candidates benefit from Nutriband’s scalable platform, and the technology is on track for global patent protection.

To view the full article, visit https://ibn.fm/QdzAd

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients

Clene (NASDAQ: CLNN), together with its subsidiary Clene Nanomedicine Inc., is preparing to initiate neurofilament biomarker analyses for its lead drug candidate CNM-Au8(R) in ALS, following feedback from the FDA during a recent Type C meeting. Slated for early Q4 2025, the analyses will assess changes in neurofilament light chain (“NfL”)—a recognized marker for neurodegeneration—among nearly 200 patients treated through the Expanded Access Program for CNM-Au8.

“We are encouraged by the FDA’s collaborative approach and their constructive feedback on our NfL biomarker analysis plan from the ongoing NIH-sponsored EAP program,” said Benjamin Greenberg, MD, Head of Medical at Clene. “With two additional FDA meetings scheduled to discuss long-term ALS survival results and the End-of-Phase 2 MS results, we are advancing our ALS and MS programs to deliver an innovative therapy for people living with neurodegenerative diseases.”

To view the full article, visit https://ibn.fm/HnqKl

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment